Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

859.88 -18.41 (-2.10%)
Official Closing Price Updated: 7:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,727,506
Open 872.50
Bid (Size) 846.16 (1)
Ask (Size) 864.30 (1)
Prev. Close 878.29
Today's Range 854.27 - 878.34
52wk Range 446.56 - 966.10
Shares Outstanding N/A
Dividend Yield 0.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Investors have strong opinions on Tesla but not on LVMH or Eli Lilly, Musk agrees on Twitter. Tesla's controversial CEO and recent financial struggles may explain heightened interest. 
Via Benzinga
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Via Benzinga

Performance

YTD
+45.20%
+45.20%
1 Month
-3.40%
-3.40%
3 Month
+17.44%
+17.44%
6 Month
+35.69%
+35.69%
1 Year
+87.94%
+87.94%

More News

Read More
3 Fabulous Growth Stocks to Buy and Hold Forever
Via InvestorPlace
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Via Benzinga
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
Via The Motley Fool
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
Via The Motley Fool
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
Via InvestorPlace
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Via Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Via Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Via The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Via The Motley Fool
SPDR ETF Report For Friday, July 19
Via Talk Markets
Topics ETFs
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Via Benzinga
Is Viking Therapeutics a Millionaire-Maker?
Via The Motley Fool
Here's How Saving Just $10 Per Day for 30 Years Can Create a $1 Million Portfolio
Via The Motley Fool
Nvidia Recently Completed a 10-for-1 Stock Split: Here Are the 3 Likeliest Candidates to Become Wall Street's Next Stock-Split Stocks
Via The Motley Fool
Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.